Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B

Abstract Background and Aim Although tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as first‐line treatment for patients with chronic hepatitis B, there are only a few studies comparing sequential therapy from ETV to TAF and continuous ETV monotherapy in patients with mainta...

Full description

Bibliographic Details
Main Authors: Norio Itokawa, Masanori Atsukawa, Akihito Tsubota, Koichi Takaguchi, Makoto Nakamuta, Atsushi Hiraoka, Keizo Kato, Hiroshi Abe, Shigeru Mikami, Noritomo Shimada, Makoto Chuma, Akito Nozaki, Haruki Uojima, Chikara Ogawa, Toru Asano, Joji Tani, Asahiro Morishita, Tomonori Senoh, Naoki Yamashita, Tsunekazu Oikawa, Yoshihiro Matsumoto, Mai Koeda, Yuji Yoshida, Tomohide Tanabe, Tomomi Okubo, Taeang Arai, Korenobu Hayama, Ai‐Nakagawa Iwashita, Chisa Kondo, Toshifumi Tada, Hidenori Toyoda, Takashi Kumada, Katsuhiko Iwakiri
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:JGH Open
Subjects:
entecavir
hepatitis B surface antigen
nucleos(t)ide analogs
tenofovir alafenamide
Online Access:https://doi.org/10.1002/jgh3.12443

Internet

https://doi.org/10.1002/jgh3.12443

Similar Items